Herold N

Targeting IMPDH to inhibit SAMHD1 in KMT2A-rearranged leukaemia.

Klootsema Y, Tsesmetzis N, Sharma S, ..., Lilienthal I, Herold N

Cell Cycle 25 (1) 1-19 [2026-12-00; online 2025-12-15]

SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms.

Thier J, Hofmann S, Kirchhof KM, ..., Moura PL, Lundin V

Leukemia 39 (11) 2801-2811 [2025-11-00; online 2025-08-26]

Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.

Rudd SG, Tsesmetzis N, Sanjiv K, ..., Helleday T, Herold N

EMBO Mol Med 12 (3) e10419 [2020-03-06; online 2020-01-17]

Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism.

Tsesmetzis N, Paulin CBJ, Rudd SG, Herold N

Cancers (Basel) 10 (7) - [2018-07-23; online 2018-07-23]

SAMHD1 protects cancer cells from various nucleoside-based antimetabolites.

Herold N, Rudd SG, Sanjiv K, ..., Henter JI, Schaller T

Cell Cycle 16 (11) 1029-1038 [2017-06-03; online 2017-04-24]

SAMHD1 is a barrier to antimetabolite-based cancer therapies.

Rudd SG, Schaller T, Herold N

Mol Cell Oncol 4 (2) e1287554 [2017-02-03; online 2017-02-03]

Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.

Herold N, Rudd SG, Ljungblad L, ..., Helleday T, Schaller T

Nat. Med. 23 (2) 256-263 [2017-02-00; online 2017-01-09]